Compare Vipshop Holdings Ltd - ADR (VIPS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vipshop Holdings Ltd - ADR vs GeneDx Holdings Corp — how do they compare? Vipshop Holdings Ltd - ADR trades at $12.71 (market cap $6.05B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Vipshop Holdings Ltd - ADR is far larger — about 3× GeneDx Holdings Corp's market cap, and Vipshop Holdings Ltd - ADR pays a 4.87% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vipshop Holdings Ltd - ADR for 49 Days and GeneDx Holdings Corp for 19 Days on average.
| VIPS | WGS | |
|---|---|---|
Market Cap | $6.05B | $2.02B |
Volume | 3,719,230 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $20.29 | $167.51 |
52-Week Low | $12.09 | $34.51 |
Typical Hold Time | 49 Days | 19 Days |
Enterprise Value | $2.87B | $2.05B |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vipshop Holdings trades at $12.77, showing modest daily gains of 0.16%. The stock presents compelling value with a P/E of 4.12 and P/S of 0.41, significantly below sector averages. Recent earnings showed mixed results with Q2 2026 missing expectations, but the company maintains strong profitability with 9.82% net margins and 24.44% ROE. Technical indicators show a bullish overall signal despite recent price consolidation near key support levels.
The investment case balances deep valuation discounts against growth challenges. Analyst consensus targets $16.17 (26% upside) with 54% buy ratings, though recent earnings misses and consumer spending concerns warrant caution. Strong cash generation and shareholder returns provide downside protection, making VIPS attractive for value investors despite near-term headwinds.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
